Publications by authors named "Lawrence Deckelbaum"

Claim this Profile
E
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
Thomas J Povsic, Serge Korjian, M Cecilia Bahit, Gerald Chi, Danielle Duffy, Lawrence I Deckelbaum

J Am Coll Cardiol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
C Michael Gibson, Danielle Duffy, Serge Korjian, M Cecilia Bahit, Gerald Chi, Lawrence I Deckelbaum

N Engl J Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
C Michael Gibson, Syed Hassan A Kazmi, Serge Korjian, Gerald Chi, Adam T Phillips, Lawrence I Deckelbaum

J Cardiovasc Pharmacol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early and late recurrent cardiovascular events among high-risk patients with an acute coronary syndrome: Meta-analysis of phase III studies and implications on trial design.
Gerald Chi, Jane J Lee, Syed H A Kazmi, Clara Fitzgerald, Sahar Memar Montazerin, Lawrence I Deckelbaum

Clin Cardiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
C Michael Gibson, John J P Kastelein, Adam T Phillips, Philip E Aylward, Megan K Yee, Lawrence I Deckelbaum

Am Heart J· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.
Andreas Gille, Danielle Duffy, Michael A Tortorici, Samuel D Wright, Lawrence I Deckelbaum

J Clin Pharmacol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
C Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, Megan Yee, Lawrence I Deckelbaum

Circulation· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing New Treatments for Heart Failure: Focus on the Heart.
Mihai Gheorghiade, Christopher J Larson, Sanjiv J Shah, Stephen J Greene, John G F Cleland, Lawrence I Deckelbaum

Circ Heart Fail· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.
Mihai Gheorghiade, Stephen J Greene, Piotr Ponikowski, Aldo P Maggioni, Jerzy Korewicki, Lawrence I Deckelbaum

Eur J Heart Fail· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.
Roger J Hajjar, Krisztina Zsebo, Lawrence Deckelbaum, Craig Thompson, Jeff Rudy

J Card Fail· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis